Amílcar Falcão

ORCID iD
orcid.org/0000-0002-3854-6549
  • Also known as
  • Show details Hide details
A. Falcao,

Sources:
Amílcar Falcão (2015-10-03)

A. Falcão,

Sources:
Amílcar Falcão (2015-10-03)

A.C. Falcao,

Sources:
Amílcar Falcão (2015-10-03)

Amílcar Celta Falcão,

Sources:
Amílcar Falcão (2015-10-03)

Falcao A.,

Sources:
Amílcar Falcão (2015-10-03)

Falcão A.,

Sources:
Amílcar Falcão (2015-10-03)

Falcão A.C.

Sources:
Amílcar Falcão (2015-10-03)

  • Keywords
  • Show details Hide details
Pharmacology,

Sources:
Amílcar Falcão (2014-01-14)

Pharmacometrics

Sources:
Amílcar Falcão (2014-01-14)

  • Other IDs
  • Show details Hide details
ResearcherID: G-6611-2013

Sources:
Clarivate Analytics (2013-06-29)

Scopus Author ID: 25639474900

Sources:
Scopus to ORCID (2014-06-07)

Biography

Amilcar Falcão graduated in Pharmaceutical Sciences at the University of Coimbra, where he also obtained his PhD and his Aggregation with Specialization in Pharmacology. He is Full Professor, Director of the Institute for Interdisciplinary Research, and accumulates the functions of Vice-Rector of the University of Coimbra in the area of Research & Innovation. He is Senior Researcher at the Center for Neuroscience and Cell Biology (CNC) and leader of the the Pharmacometrics group. His extensive scientific production comprises approximately 400 publications (among articles, book chapters and abstracts in refereed journals) and many scientific papers, posters and oral presentations (dozens of them by invitation), having the overwhelming majority been international and referee submitted. He supervised 16 master and 8 PhD theses, and is currently responsible for the supervision of 10 PhD and 3 Master theses. He is a regularly invited reviewer and member of the editorial board of several scientific journals. He has been several times distinguished with national and international awards, which reinforces the visibility and quality of his work throughout his career. Keeping a strong connection with the pharmaceutical industry along his career, the collaboration with the laboratories BIAL (Portugal) shall be highlighted, where he actively and significantly participates in his program of new drugs development. His contribution lies both in clinical and non-clinical testing (biostatistics, pharmacokinetics and pharmacodynamics), having been involved in over a hundred studies in total. His portfolio includes a set of molecules with particular emphasis to eslicarbazepine acetate, which was the first Portuguese commercialized drug (Zebinix ®), and more recently, Opicapone (a new drug for Parkinson's disease). He is also Technical Director of the company ICNAS Produção (a company 100% owned by the University of Coimbra), and participated actively in obtaining the first radiopharmaceutical developed and registered in Portugal (fludeoxyglucose [18F] UC).
  • : , ,

    {{group.getActive().startDate.year}}-{{group.getActive().startDate.month}}-{{group.getActive().startDate.day}} to present {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}} {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}}
     ()
    Source: {{(group.getActive().sourceName == null || group.getActive().sourceName == '') ? group.getActive().source : group.getActive().sourceName}}
    Created:
No education added yet
  • : , ,

    {{group.getActive().startDate.year}}-{{group.getActive().startDate.month}}-{{group.getActive().startDate.day}} to present {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}} {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}}
     ()
    Source: {{(group.getActive().sourceName == null || group.getActive().sourceName == '') ? group.getActive().source : group.getActive().sourceName}}
    Created:
No employment added yet
No publications added yet